Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10595683rdf:typepubmed:Citationlld:pubmed
pubmed-article:10595683lifeskim:mentionsumls-concept:C0002395lld:lifeskim
pubmed-article:10595683lifeskim:mentionsumls-concept:C0017337lld:lifeskim
pubmed-article:10595683lifeskim:mentionsumls-concept:C0021920lld:lifeskim
pubmed-article:10595683lifeskim:mentionsumls-concept:C0528480lld:lifeskim
pubmed-article:10595683lifeskim:mentionsumls-concept:C0004083lld:lifeskim
pubmed-article:10595683lifeskim:mentionsumls-concept:C1882417lld:lifeskim
pubmed-article:10595683lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:10595683lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:10595683lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:10595683pubmed:issue5lld:pubmed
pubmed-article:10595683pubmed:dateCreated1999-12-28lld:pubmed
pubmed-article:10595683pubmed:abstractTextSeveral alleles of introns or untranslated regions in the presenilin-1 (PS-1) and presenilin-2 (PS-2) genes have been reported to behave as risk factors for senile Alzheimer's disease (AD). On the other hand, mutations in the three presenile AD genes also have been identified in a small number of sporadic presenile AD and senile AD cases. The present study evaluated the genetic contributions of PS-2 exons and introns to 56 senile and 18 Japanese cases of presenile AD using polymerase chain reaction single-strand conformation polymorphism analysis. In the PS-2 gene, one exonic polymorphic site without amino acid substitution, 9 intronic polymorphic sites, and 2 intronic variant sites were detected. However, in all cases, amino acid substitutions in exons between 4 and 12 of the PS-2 gene were not observed. The risk factors of senile and presenile AD were evaluated using a population-based study of restriction cleavages between patients and controls in introns 3, 4, 10 and 11. Regarding PS-2, there was no association between AD and intronic polymorphisms.lld:pubmed
pubmed-article:10595683pubmed:languageenglld:pubmed
pubmed-article:10595683pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10595683pubmed:citationSubsetIMlld:pubmed
pubmed-article:10595683pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10595683pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10595683pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10595683pubmed:statusMEDLINElld:pubmed
pubmed-article:10595683pubmed:monthOctlld:pubmed
pubmed-article:10595683pubmed:issn1323-1316lld:pubmed
pubmed-article:10595683pubmed:authorpubmed-author:HondaMMlld:pubmed
pubmed-article:10595683pubmed:authorpubmed-author:MiyakawaTTlld:pubmed
pubmed-article:10595683pubmed:authorpubmed-author:IgataTTlld:pubmed
pubmed-article:10595683pubmed:authorpubmed-author:YamamuraK IKIlld:pubmed
pubmed-article:10595683pubmed:authorpubmed-author:HitoshiYYlld:pubmed
pubmed-article:10595683pubmed:authorpubmed-author:OgomoriKKlld:pubmed
pubmed-article:10595683pubmed:authorpubmed-author:KanameTTlld:pubmed
pubmed-article:10595683pubmed:authorpubmed-author:Igata-YiRRlld:pubmed
pubmed-article:10595683pubmed:issnTypePrintlld:pubmed
pubmed-article:10595683pubmed:volume53lld:pubmed
pubmed-article:10595683pubmed:ownerNLMlld:pubmed
pubmed-article:10595683pubmed:authorsCompleteYlld:pubmed
pubmed-article:10595683pubmed:pagination579-85lld:pubmed
pubmed-article:10595683pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10595683pubmed:meshHeadingpubmed-meshheading:10595683...lld:pubmed
pubmed-article:10595683pubmed:meshHeadingpubmed-meshheading:10595683...lld:pubmed
pubmed-article:10595683pubmed:meshHeadingpubmed-meshheading:10595683...lld:pubmed
pubmed-article:10595683pubmed:meshHeadingpubmed-meshheading:10595683...lld:pubmed
pubmed-article:10595683pubmed:meshHeadingpubmed-meshheading:10595683...lld:pubmed
pubmed-article:10595683pubmed:meshHeadingpubmed-meshheading:10595683...lld:pubmed
pubmed-article:10595683pubmed:meshHeadingpubmed-meshheading:10595683...lld:pubmed
pubmed-article:10595683pubmed:meshHeadingpubmed-meshheading:10595683...lld:pubmed
pubmed-article:10595683pubmed:meshHeadingpubmed-meshheading:10595683...lld:pubmed
pubmed-article:10595683pubmed:meshHeadingpubmed-meshheading:10595683...lld:pubmed
pubmed-article:10595683pubmed:meshHeadingpubmed-meshheading:10595683...lld:pubmed
pubmed-article:10595683pubmed:meshHeadingpubmed-meshheading:10595683...lld:pubmed
pubmed-article:10595683pubmed:meshHeadingpubmed-meshheading:10595683...lld:pubmed
pubmed-article:10595683pubmed:meshHeadingpubmed-meshheading:10595683...lld:pubmed
pubmed-article:10595683pubmed:year1999lld:pubmed
pubmed-article:10595683pubmed:articleTitleNovel intronic polymorphisms in the presenilin-2 gene and a case-control association study of Alzheimer's disease.lld:pubmed
pubmed-article:10595683pubmed:affiliationDepartment of Developmental Genetics, Institute of Molecular Embryology and Genetics, Kumamoto University School of Medicine, Japan.lld:pubmed
pubmed-article:10595683pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10595683pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed